BMC Medical’s G3X APAP devices were misbranded/adulterated after significant changes without a new 510(k) and an unreported firmware fix.
What happened
FDA inspected 3B Medical, Inc. (d.b.a. React Health) in Dublin, Ohio, from December 1, 2025 through December 10, 2025, and determined that BMC Medical is the specification developer and 510(k) owner of imported ventilator devices. FDA found that BMC made significant design, material, and software changes to the cleared Luna APAP and marketed them as G3X APAP without a new 510(k); FDA also found BMC failed to report a firmware correction meant to prevent unexpected shutdown and loss of therapy.
What FDA found
FDA says the G3X APAP was adulterated because BMC did not have an approved premarket approval application or an investigational device exemption for it.
section 501(f)(1)(B), 21 U.S.C. § 351(f)(1)(B); section 515(a), 21 U.S.C. § 360e(a); section 520(g), 21 U.S.C. § 360j(g)FDA says BMC made significant design, material, and software changes to the cleared Luna APAP and marketed the G3X APAP without submitting a new 510(k) premarket notification.
section 502(o), 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k); 21 CFR 807.81(a)(3)FDA says BMC did not submit a Report of Correction or Removal within 10 working days for a firmware update from G3-2.00.76 to G3-2.00.77 intended to prevent unexpected shutdown and loss of therapy.
section 502(t)(2), 21 U.S.C. § 352(t)(2); section 519, 21 U.S.C. § 360i; 21 CFR 806.10
What FDA wants
FDA tells BMC to cease activities that result in misbranding or adulteration and to respond in writing within 15 business days with the specific steps and corrective actions taken or planned to address the violations.
Who should pay attention
- companies that import or distribute BMC/React Health sleep-apnea devices
- specification developers and 510(k) owners of cleared medical devices
- quality teams responsible for medical device correction and removal reports
This is a summary. Read the original letter on fda.gov.